/SCLX
SCLX Stock - Scilex Holding Company
Healthcare|Drug Manufacturers - GeneralNASDAQ
$14.35-1.78%
$0.26 (-1.78%) • Dec 19
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.51
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $15.79
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SCLX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.21 – $14.49
TARGET (TP)$16.50
STOP LOSS$13.20
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.34
52W High$34.27
52W Low$3.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $56.59M | $46.74M | $38.03M | $31.32M | $23.56M |
| Gross Profit | $39.90M | $31.06M | $27.24M | $27.68M | $21.41M |
| Gross Margin | 70.5% | 66.5% | 71.6% | 88.4% | 90.9% |
| Operating Income | $-83,396,000 | $-105,431,000 | $-50,634,000 | $-35,838,000 | $-35,258,000 |
| Net Income | $-72,807,000 | $-114,331,000 | $-23,364,000 | $-88,424,000 | $-47,519,000 |
| Net Margin | -128.7% | -244.6% | -61.4% | -282.4% | -201.7% |
| EPS | $-19.43 | $-44.85 | $-6.09 | $-23.29 | $-0.01 |
Company Overview
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↓ 19.9% Downside
Now
$4
Low
$12
Average
$22
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 27th 2025 | D. Boral Capital | Initiation | Buy | $22 |
| October 16th 2024 | Alliance Global Partners | Initiation | Buy | $14 |
| June 13th 2024 | Rodman & Renshaw | Initiation | Buy | $13 |
| October 16th 2023 | B. Riley Securities | Initiation | Buy | $4 |
| October 13th 2023 | B. Riley Securities | Initiation | Buy | $4 |
| October 9th 2023 | H.C. Wainwright | Initiation | Buy | $12 |
Earnings History & Surprises
SCLXBeat Rate
22%
Last 9 quarters
Avg Surprise
-1158.6%
EPS vs Estimate
Beats / Misses
2/7
Last 12 quarters
Latest EPS
$-22.17
Q4 2025
EPS Surprise History
Q1 24
-19.1%
$-8.74vs$-7.34
Q2 24
-116.4%
$-9.09vs$-4.20
Q3 24
+10.0%
$-6.29vs$-6.99
Q1 25
-3600.0%
$-6.29vs$-0.17
Q1 25
-150.0%
$-0.25vs$-0.10
Q2 25
+46.2%
$-2.26vs$-4.20
Q3 25
-1709.8%
$-7.42vs$-0.41
Q4 25
-4617.0%
$-22.17vs$-0.47
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | $-0.47 | $-22.17 | -4617.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.41 | $-7.42 | -1709.8% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-4.20 | $-2.26 | +46.2% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.10 | $-0.25 | -150.0% | ✗ MISS |
Q1 2025 | Jan 17, 2025 | $-0.17 | $-6.29 | -3600.0% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-6.99 | $-6.29 | +10.0% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-4.20 | $-9.09 | -116.4% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-7.34 | $-8.74 | -19.1% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-5.94 | $-22.03 | -270.9% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | — | $-5.59 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.22 | — | — |
Q1 2023 | Mar 7, 2023 | — | $-4.66 | — | — |
Q3 2022 | Sep 30, 2022 | — | $5.65 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-4.42 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-2.27 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.26 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.33 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-4.51 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-4.51 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-2.95 | — | — |
Latest News
Scilex Raises $20M As Investors Exercise Stock Warrants To Support Non-Opioid Pain Drug Strategy
📈 PositiveBenzinga•Nov 24, 2025, 11:03 AM
Datavault AI Board Approves Distribution Of Dream Bowl Draft Meme Coins To Eligible Holders Of Scilex Holding
📈 PositiveBenzinga•Nov 11, 2025, 01:42 PM•Also:
Scilex Signs MOU With Biconomy To Explore Crypto Trading Services And Treasury Strategy
📈 PositiveBenzinga•Sep 24, 2025, 02:13 PM
Semnur Pharmaceuticals, A Majority-Owned Subsidiary Of Scilex Holding Company Announces That Shareholders Of Denali Capital Acquisition Corp Have Approved The Previously Announced Business Combination With Semnur
📈 PositiveBenzinga•Sep 4, 2025, 01:05 PM
Scilex Holding Subsidiary Semnur, With Denali Capital, Secures $20M Private Placement At $16 Per Share To Advance SP-102 Sciatica Therapy
📈 PositiveBenzinga•Aug 21, 2025, 10:06 AM
Frequently Asked Questions about SCLX
What is SCLX's current stock price?
Scilex Holding Company (SCLX) is currently trading at $14.35 per share. The stock has moved -1.78% today.
What is the analyst price target for SCLX?
No analyst price targets are currently available for this stock.
What sector is Scilex Holding Company in?
Scilex Holding Company operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NASDAQ exchange.
What is SCLX's market cap?
Scilex Holding Company has a market capitalization of $0.12 billion, making it a small-cap company.
Does SCLX pay dividends?
No, Scilex Holding Company does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
AGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
CTOR
Citius Oncology, Inc.
$1.39
Mkt Cap: $0.1B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
IXHL
Incannex Healthcare Limited
$0.44
Mkt Cap: $0.0B
LUCD
Lucid Diagnostics Inc.
$1.12
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to SCLX for comparison